Hollings Home  
 
Melanie B Thomas, MD
Associate Professor of Medicine
Hematology/Oncology
College of Medicine
MUSC

Email: thomasmb@musc.edu
 
       Print This Page
       
 
 


 

Melanie B Thomas, MD

Return to Search Page  

Research Interest:

I am a medical oncologist with a clinical practice and research interests focusing on gastrointestinal malignancies, specifically pancreatic, hepatobiliary and colorectal cancers. I have been the Principal Investigator on numerous clinical trials of novel biologic anti-cancer agents in GI malignancies. The spectrum of clinical trials I have led or been a clinical collaborator on includes investigator-initiated, SWOG, industry sponsored, and CTEP-sponsored Phase I, II and randomized Phase II trials. As the Associate Director of Clinical Investigations at the Medical University of South Carolina Hollings Cancer Center, I wholeheartedly support the endeavors of my colleagues in the Cancer Center.

Honors:
Grace E. DeWolff Endowed Chair in Medical Oncology, SmartState Center of Economic Excellence

Positions:
Associate Director of Clinical Investigations, Hollings Cancer Center, Medical University of South Carolina

Selected Publications:

1.Esnaola NF, Chaudhary UB, O'Brien P, Garrett-Mayer E, Camp ER, Thomas MB, Cole DJ, Montero AJ, Hoffman BJ, Romagnuolo J, Orwat KP, Marshall DT. Phase 2 trial of induction gemcitabine, oxaliplatin, and cetuximab followed by selective capecitabine-based chemoradiation in patients with borderline resectable or unresectable locally advanced pancreatic cancer. Int J Radiat Oncol Biol Phys. .88(4):837-44, 2014.
View in: PubMed

2.Thomas MB. Systemic and targeted therapy for biliary tract tumors and primary liver tumors. Surg Oncol Clin N Am. .23(2):369-81, 2013.
View in: PubMed

3.Wallace K, Sterba KR, Gore E, Lewin DN, Ford ME, Thomas MB, Alberg AJ. Prognostic factors in relation to racial disparity in advanced colorectal cancer survival. Clin Colorectal Cancer. .12(4):287-93, 2013. PMCID: PMC3863997
View in: PubMed

4.Maithel SK, Gamblin TC, Kamel I, Corona-Villalobos CP, Thomas M, Pawlik TM. Multidisciplinary approaches to intrahepatic cholangiocarcinoma. Cancer. .119(22):3929-42, 2013.
View in: PubMed

5.Wallace K, Hill EG, Lewin DN, Williamson G, Oppenheimer S, Ford ME, Wargovich MJ, Berger FG, Bolick SW, Thomas MB, Alberg AJ. Racial disparities in advanced-stage colorectal cancer survival. Cancer Causes Control. .24(3):463-71, 2013. PMCID: PMC3574218
View in: PubMed

6.Sterba KR, Zapka J, Gore EI, Ford ME, Ford DW, Thomas M, Wallace K. Exploring dimensions of coping in advanced colorectal cancer: implications for patient-centered care. J Psychosoc Oncol. .31(5):517-39, 2013.
View in: PubMed

7.Yang Y, Mauldin PD, Ebeling M, Hulsey TC, Liu B, Thomas MB, Camp ER, Esnaola NF. Effect of metabolic syndrome and its components on recurrence and survival in colon cancer patients. Cancer. .119(8):1512-20, 2012.
View in: PubMed

8.Friday B, Lassere Y, Meyers CA, Mita A, Abbruzzese JL, Thomas MB. A phase I study to determine the safety and pharmacokinetics of intravenous administration of TAS-106 once per week for three consecutive weeks every 28 days in patients with solid tumors. Anticancer Res. .32(5):1689-96, 2012.
View in: PubMed

9.Kaseb AO, Garrett-Mayer E, Morris JS, Xiao L, Lin E, Onicescu G, Hassan MM, Hassabo HM, Iwasaki M, Deaton FL, Abbruzzese JL, Thomas MB. Efficacy of bevacizumab plus erlotinib for advanced hepatocellular carcinoma and predictors of outcome: final results of a phase II trial. Oncology. .82(2):67-74, 2012.
View in: PubMed

10.Park JW, Finn RS, Kim JS, Karwal M, Li RK, Ismail F, Thomas M, Harris R, Baudelet C, Walters I, Raoul JL. Phase II, open-label study of brivanib as first-line therapy in patients with advanced hepatocellular carcinoma. Clin Cancer Res. .17(7):1973-83, 2011.
View in: PubMed

11.Hammond-Thelin LA, Thomas MB, Iwasaki M, Abbruzzese JL, Lassere Y, Meyers CA, Hoff P, de Bono J, Norris J, Matsushita H, Mita A, Rowinsky EK. Phase I and pharmacokinetic study of 3'-C-ethynylcytidine (TAS-106), an inhibitor of RNA polymerase I, II and III,in patients with advanced solid malignancies. Invest New Drugs. .30(1):316-26, 2010.
View in: PubMed

12.Thomas MB, Jaffe D, Choti MM, Belghiti J, Curley S, Fong Y, Gores G, Kerlan R, Merle P, O'Neil B, Poon R, Schwartz L, Tepper J, Yao F, Haller D, Mooney M, Venook A. Hepatocellular carcinoma: consensus recommendations of the National Cancer Institute Clinical Trials Planning Meeting. J Clin Oncol. .28(25):3994-4005, 2010. PMCID: PMC2940397
View in: PubMed

13.Burak KW, Thomas MB, Zhu AX. Nonoperative therapies for combined modality treatment of hepatocellular cancer: expert consensus conference. HPB (Oxford). .12(5):321-2, 2010. PMCID: PMC2951819
View in: PubMed

14.Thomas MB. CanLiv: Shining a Light on Cancer's Neglected "Orphans". Gastrointest Cancer Res. .3(3):131-2, 2009. PMCID: PMC2713140
View in: PubMed

15.Hassan MM, Kaseb A, Li D, Patt YZ, Vauthey JN, Thomas MB, Curley SA, Spitz MR, Sherman SI, Abdalla EK, Davila M, Lozano RD, Hassan DM, Chan W, Brown TD, Abbruzzese JL. Association between hypothyroidism and hepatocellular carcinoma: a case-control study in the United States. Hepatology. .49(5):1563-70, 2009. PMCID: PMC3715879
View in: PubMed

16.Thomas MB. Toward improved outcomes in hepatocellular carcinoma: overcoming the challenges of an "orphan" tumor. Gastrointest Cancer Res. .3(2):73, 2009. PMCID: PMC2684725
View in: PubMed

17.Thomas M. Molecular targeted therapy for hepatocellular carcinoma. J Gastroenterol. .44 Suppl 19:136-41, 2009.
View in: PubMed

18.Thomas MB, Morris JS, Chadha R, Iwasaki M, Kaur H, Lin E, Lin E, Kaseb A, Glover K, Davila M, Abbruzzese J. Phase II trial of the combination of bevacizumab and erlotinib in patients who have advanced hepatocellular carcinoma. J Clin Oncol. .27(6):843-50, 2009.
View in: PubMed

19.García P, Manterola C, Araya JC, Villaseca M, Guzmán P, Sanhueza A, Thomas M, Alvarez H, Roa JC. Promoter methylation profile in preneoplastic and neoplastic gallbladder lesions. Mol Carcinog. .48(1):79-89, 2009.
View in: PubMed

20.Hassan MM, Spitz MR, Thomas MB, Curley SA, Patt YZ, Vauthey JN, Glover KY, Kaseb A, Lozano RD, El-Deeb AS, Nguyen NT, Wei SH, Chan W, Abbruzzese JL, Li D. The association of family history of liver cancer with hepatocellular carcinoma: a case-control study in the United States. J Hepatol. .50(2):334-41, 2008. PMCID: PMC2658718
View in: PubMed

21.Hassan MM, Spitz MR, Thomas MB, El-Deeb AS, Glover KY, Nguyen NT, Chan W, Kaseb A, Curley SA, Vauthey JN, Ellis LM, Abdalla E, Lozano RD, Patt YZ, Brown TD, Abbruzzese JL, Li D. Effect of different types of smoking and synergism with hepatitis C virus on risk of hepatocellular carcinoma in American men and women: case-control study. Int J Cancer. .123(8):1883-91, 2008. PMCID: PMC2673571
View in: PubMed

22.Borghero Y, Crane CH, Szklaruk J, Oyarzo M, Curley S, Pisters PW, Evans D, Abdalla EK, Thomas MB, Das P, Wistuba II, Krishnan S, Vauthey JN. Extrahepatic bile duct adenocarcinoma: patients at high-risk for local recurrence treated with surgery and adjuvant chemoradiation have an equivalent overall survival to patients with standard-risk treated with surgery alone. Ann Surg Oncol. .15(11):3147-56, 2008.
View in: PubMed

23.Overman MJ, Varadhachary G, Kopetz S, Thomas MB, Fukushima M, Kuwata K, Mita A, Wolff RA, Hoff PM, Xiong H, Abbruzzese JL. Phase 1 study of TAS-102 administered once daily on a 5-day-per-week schedule in patients with solid tumors. Invest New Drugs. .26(5):445-54, 2008.
View in: PubMed

24.Higginbotham KB, Lozano R, Brown T, Patt YZ, Arima T, Abbruzzese JL, Thomas MB. A phase I/II trial of TAC-101, an oral synthetic retinoid, in patients with advanced hepatocellular carcinoma. J Cancer Res Clin Oncol. .134(12):1325-35, 2008.
View in: PubMed

25.Thomas MB. Targeted therapies for cancer of the gallbladder. Curr Opin Gastroenterol. .24(3):372-6, 2008.
View in: PubMed

26.Miyahara N, Shoda J, Ishige K, Kawamoto T, Ueda T, Taki R, Ohkohchi N, Hyodo I, Thomas MB, Krishnamurthy S, Carraway KL, Irimura T. MUC4 interacts with ErbB2 in human gallbladder carcinoma: potential pathobiological implications. Eur J Cancer. .44(7):1048-56, 2008.
View in: PubMed

27.Thomas MB, Wright JD, Leiser AL, Chi DS, Mutch DG, Podratz KC, Dowdy SC. Clear cell carcinoma of the cervix: a multi-institutional review in the post-DES era. Gynecol Oncol. .109(3):335-9, 2008. PMCID: PMC3667392
View in: PubMed

28.Thomas MB. Systemic therapy for hepatocellular carcinoma. Cancer J. .14(2):123-7, 2008.
View in: PubMed

29.Thomas MB, Lawrence TS. From the guest editors. Hepatocellular carcinoma. Cancer J. .14(2):94, 2008.
View in: PubMed

30.Thomas MB, O'Beirne JP, Furuse J, Chan AT, Abou-Alfa G, Johnson P. Systemic therapy for hepatocellular carcinoma: cytotoxic chemotherapy, targeted therapy and immunotherapy. Ann Surg Oncol. .15(4):1008-14, 2008.
View in: PubMed

31.Thomas MB, Davila M, Abbruzzese JL. Stemming the tide of hepatitis B virus related hepatocellular carcinoma? J Clin Oncol. .26(2):172-4, 2008.
View in: PubMed

32.Thomas MB, Tetzlaff E, Lozano R, Samp L, Butler CE, Gannon C, Hamilton S, Vauthey JN, Abdalla E. Curing hepatocellular carcinomatosis with biologic therapy and surgery: achieving the impossible? J Surg Oncol. .97(1):82-4, 2008.
View in: PubMed

33.Ribero D, Wang H, Donadon M, Zorzi D, Thomas MB, Eng C, Chang DZ, Curley SA, Abdalla EK, Ellis LM, Vauthey JN. Bevacizumab improves pathologic response and protects against hepatic injury in patients treated with oxaliplatin-based chemotherapy for colorectal liver metastases. Cancer. .110(12):2761-7, 2007.
View in: PubMed

34.Kawamoto T, Krishnamurthy S, Tarco E, Trivedi S, Wistuba II, Li D, Roa I, Roa JC, Thomas MB. HER Receptor Family: Novel Candidate for Targeted Therapy for Gallbladder and Extrahepatic Bile Duct Cancer. Gastrointest Cancer Res. .1(6):221-7, 2007. PMCID: PMC2631213
View in: PubMed

35.Thomas MB, Mariani A, Cliby WA, Keeney GL, Podratz KC, Dowdy SC. Role of cytoreduction in stage III and IV uterine papillary serous carcinoma. Gynecol Oncol. .107(2):190-3, 2007.
View in: PubMed

36.Thomas MB, Chadha R, Glover K, Wang X, Morris J, Brown T, Rashid A, Dancey J, Abbruzzese JL. Phase 2 study of erlotinib in patients with unresectable hepatocellular carcinoma. Cancer. .110(5):1059-67, 2007.
View in: PubMed

37.Thomas MB, Mariani A, Cliby WA, Keeney GA, Podratz KC, Dowdy SC. Role of systematic lymphadenectomy and adjuvant therapy in stage I uterine papillary serous carcinoma. Gynecol Oncol. .107(2):186-9, 2007.
View in: PubMed

38.Wu Q, Kiguchi K, Kawamoto T, Ajiki T, Traag J, Carbajal S, Ruffino L, Thames H, Wistuba I, Thomas M, Vasquez KM, DiGiovanni J. Therapeutic effect of rapamycin on gallbladder cancer in a transgenic mouse model. Cancer Res. .67(8):3794-800, 2007.
View in: PubMed

39.Thomas MB. Biological characteristics of cancers in the gallbladder and biliary tract and targeted therapy. Crit Rev Oncol Hematol. .61(1):44-51, 2007.
View in: PubMed

40.Ribero D, Abdalla EK, Thomas MB, Vauthey JN. Liver resection in the treatment of hepatocellular carcinoma. Expert Rev Anticancer Ther. .6(4):567-79, 2006.
View in: PubMed

41.Thomas MB, Abbruzzese JL. Opportunities for targeted therapies in hepatocellular carcinoma. J Clin Oncol. .23(31):8093-108, 2005.
View in: PubMed

42.Thomas MB, Zhu AX. Hepatocellular carcinoma: the need for progress. J Clin Oncol. .23(13):2892-9, 2005.
View in: PubMed

43.Pawlik TM, Scoggins CR, Thomas MB, Vauthey JN. Advances in the surgical management of liver malignancies. Cancer J. .10(2):74-87, 2004.
View in: PubMed

44.Shaughnessy L, Chamblin B, McMahon L, Nair A, Thomas MB, Wakefield J, Koentgen F, Ramabhadran R. Novel approaches to models of Alzheimer's disease pathology for drug screening and development. J Mol Neurosci. .24(1):23-32, 2004.
View in: PubMed

45.Thomas MB, Koller C, Yang Y, Shen Y, O'Brien S, Kantarjian H, Davis J, Estey E. Comparison of fludarabine-containing salvage chemotherapy regimens for relapsed/refractory acute myelogenous leukemia. Leukemia. .17(5):990-3, 2003.
View in: PubMed